Marvel Biosciences Announced Grant of Deferred Share Units
Calgary, Alberta, Canada, November 10, 2025 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 35,697 deferred share units (“DSUs”) to Marvel’s three independent directors, in lieu of cash payment for directors’ fees. The DSUs will all vest on October 31, 2026. Vested DSUs shall be...
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
Calgary, Alberta, Canada, October 3, 2025 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is announcing that, further to the Company’s press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that it will be accelerating the expiry date of the warrants...
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
Calgary, Alberta – August 18, 2025 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), , a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted...
Marvel Biosciences Announces Grant of Deferred Shared Units
Calgary, Alberta, Canada, August 11, 2025 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 142,987 deferred share units (“DSUs”) to two of Marvel’s directors, in lieu of cash payment for directors’ fees. The DSUs will all vest on July 31, 2026. Vested DSUs shall be settled upon...
Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment
Calgary, Alberta – April 30, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share part of the second final data set from its preclinical Rett syndrome study conducted in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBraiN Institute. The study...
Marvel Biosciences to Give Oral Presentation at the Annual IRSF Rett Syndrome Scientific Meeting
Calgary, Alberta – April 16, 2025 – Marvel Biosciences Corp. (TSXV: MRVL, OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together “Marvel”), are pleased to announce their acceptance to give an oral presentation at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11th, 2025. Dr. Mark Williams, Chief Science Officer of Marvel, will...
Marvel Biosciences Selected to Present Alzheimer’s Research at the 2025 Alzheimer’s Association International Conference
Calgary, Alberta – April 14, 2025 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), is pleased to announce that it has been invited to present its latest research findings at the Alzheimer’s Association International Conference (AAIC), taking place in July 2025. The Company will present...
Marvel Biosciences Announces Private Placement
Calgary, Alberta, Canada, March 28, 2025 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that, subject to approval of the TSX Venture Exchange (the “TSXV”), it has closed the first tranche of a non-brokered private placement of up to 12,000,000 units (the “Units”) at a price of...
Marvel Biosciences to File for Orphan Drug Designation with the U.S. FDA for MB-204 as a Treatment for Rett Syndrome
Calgary, Alberta – March 17, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for its lead compound, MB-204, as a potential treatment for Rett Syndrome. This decision follows strong...
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
Calgary, Alberta – March 13, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. The study evaluated MB-204, Marvel’s lead compound (10 mg/kg oral once...